Kodiak Sciences Inc.(KOD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KOD Kodiak Sciences Inc.

Market Closed 03-28 16:00:00 EDT

2.91

-0.15

-4.90%

盘后2.91

+0.000.00%

17:38 EDT

High3.14	Low2.85	Vol385.17K
Open2.97	D1 Closing3.06	Amplitude9.48%
Mkt Cap152.78M	Tradable Cap93.75M	Total Shares52.50M
T/O1.14M	T/O Rate1.20%	Tradable Shares32.21M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"KOD","market":"US","secType":"STK","nameCN":"Kodiak Sciences Inc.","latestPrice":2.91,"timestamp":1743192000000,"preClose":3.06,"halted":0,"volume":385170,"hourTrading":{"tag":"盘后","latestPrice":2.91,"preClose":2.91,"latestTime":"17:38 EDT","volume":17015,"amount":49513.93,"timestamp":1743197906743},"delay":0,"floatShares":32214858,"shares":52501425,"eps":-3.646996,"marketStatus":"Market Closed","change":-0.15,"latestTime":"03-28 16:00:00 EDT","open":2.97,"high":3.14,"low":2.85,"amount":1140260.021514,"amplitude":0.094771,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.646996,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743408000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1538625600000,"exchange":"NASDAQ","adjPreClose":3.06,"preHourTrading":{"tag":"盘前","latestPrice":3.09,"preClose":3.06,"latestTime":"08:53 EDT","volume":19,"amount":58.95,"timestamp":1743166396538},"postHourTrading":{"tag":"盘后","latestPrice":2.91,"preClose":2.91,"latestTime":"17:38 EDT","volume":17015,"amount":49513.93,"timestamp":1743197906743},"volumeRatio":1.1052376351061162,"impliedVol":1.1718,"impliedVolPercentile":0.764},"requestUrl":"/m/hq/s/KOD/wiki","defaultTab":"wiki","newsList":[{"id":"2523689447","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Kodiak Sciences (KOD), Tempest Therapeutics (TPST) and EDAP TMS (EDAP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2523689447","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523689447?lang=en_us&edition=full_marsco","pubTime":"2025-03-29 01:40","pubTimestamp":1743183617,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Kodiak Sciences (KOD – Research Report), Tempest T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-kodiak-sciences-kod-tempest-therapeutics-tpst-and-edap-tms-edap?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-kodiak-sciences-kod-tempest-therapeutics-tpst-and-edap-tms-edap?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4082","EDAP","KOD","HCSG","BK4137","TPST","BK4139"],"gpt_icon":0},{"id":"2523075615","title":"Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2523075615","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523075615?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 21:45","pubTimestamp":1743169500,"startTime":"0","endTime":"0","summary":"Kodiak SciencesKOD reported a loss of 84 cents per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 90 cents. The company had incurred a loss of $1.13 per share in the year-ago quarter.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The company currently does not have any approved products in its portfolio. As a result, it has yet to generate revenues.Research and development expenses were $31.8 million in the reported quarter, down 32% year over year. The decrease was mainly due to reduced manufacturing activities and forfeitures of equity awards, partially offset by clinical activities from active studies.General and administrative expenses were $14.4 million, down 14% year over year, primarily due to lower non-cash stock-based compensation expenses.Kodiak is also enrolling patients in the phase Ib APEX study, which will evaluate its third investigational candidate, KSI-101, in two new cohorts — cohort 1 in patients w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kodiak-q4-loss-narrower-expected-134500496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4534","KOD","LU2360106780.USD","BK4505","LU0823434740.USD","LU1988902786.USD","LU2458330243.SGD","LU0081259029.USD","BK4543","LU1242518857.USD","LU2054465674.USD","LU0082616367.USD","LU1880398471.USD","IE0004445239.USD","LU1803068979.SGD","LU2098885051.SGD","BK4532","BK4605","LU2458330169.SGD","LU0979878070.USD","BK4585","LU0127658192.USD","BK4007","BK4588","LU1989764664.SGD","LU1951200564.SGD","DVAX","IE00BMPRXR70.SGD","LU1951198990.SGD","BAYRY","IE0009356076.USD","LU1559883803.SGD","IE00B5949003.HKD","LU2250418816.HKD","BK4529","BK4573","LU1064131342.USD","LU0642271901.SGD","CORT","LU0823421333.USD","BK4512","LU1852331112.SGD","LU1880398554.USD","BK4139","LU1303367103.USD","BK4141","BK4554","LU0823421416.USD","LU0823434583.USD"],"gpt_icon":1},{"id":"2522995534","title":"Kodiak Sciences Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2522995534","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522995534?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:40","pubTimestamp":1743108053,"startTime":"0","endTime":"0","summary":"Kodiak Sciences Inc reports results for the quarter ended December 31 - Earnings SummaryKodiak Sciences Inc KOD.OQ reported a quarterly adjusted loss of 84 cents per share for the quarter ended Decemb","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nL5N3QA24C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD"],"gpt_icon":0},{"id":"2522391815","title":"Kodiak Sciences Q4 EPS ($0.84) Up From ($1.13) YoY.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522391815","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522391815?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:06","pubTimestamp":1743105979,"startTime":"0","endTime":"0","summary":"Kodiak Sciences Q4 EPS ($0.84) Up From ($1.13) YoY.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44523768/kodiak-sciences-q4-eps-0-84-up-from-1-13-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD"],"gpt_icon":0},{"id":"2522753939","title":"BRIEF-Kodiak Sciences Q4 Net Income USD -44.105 Million Vs. IBES Estimate USD -45 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2522753939","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522753939?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:01","pubTimestamp":1743105708,"startTime":"0","endTime":"0","summary":"BRIEF-Kodiak Sciences Q4 Net Income USD -44.105 Million Vs. IBES Estimate USD -45 Million\n\n\nMar 27 (Reuters) - Kodiak Sciences Q4 operating expenses USD 46.179 million.\n\nQ4 operating income USD -46.179 million vs. IBES estimate USD -49.3 million\nQ4 basic EPS USD -0.84","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLXD2AFE9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","KOD"],"gpt_icon":0},{"id":"2522393805","title":"Kodiak Sciences Q4 Operating Income USD -46.179 Million VS. Ibes Estimate USD -49.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2522393805","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522393805?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:01","pubTimestamp":1743105663,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLXD2AFE9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KOD","BK4139","BK4505"],"gpt_icon":0},{"id":"2522396385","title":"Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522396385","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522396385?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:01","pubTimestamp":1743105660,"startTime":"0","endTime":"0","summary":"PALO ALTO, Calif., March 27, 2025 /PRNewswire/ -- Kodiak Sciences Inc. , today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024.\"In September of 2024 we hosted an Investor R&D Day in New York,\" said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. \"The Investor R&D Day webcast and presentation featured scientific, clinical and commercial perspectives and included key retina opinion leaders. It was an important snapshot of where we stood at that time, and where we were going – we called it Kodiak 2.0. Six months later, we are well on track.\". \"With KSI-101, we have broadened our focus into a greenfield opportunity in retina, the macular edema inflammation market. Intraocular inflammation is the fourth l","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/kodiak-sciences-announces-recent-business-200100179.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kodiak-sciences-announces-recent-business-200100179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1242518857.USD","BK4566","BK4535","BK4614","LU1064131342.USD","BK4588","BK4612","KOD","LU2250418816.HKD","BK4505","BK4551","LU1923623000.USD","BK4534","IE00B5949003.HKD","LU1988902786.USD","BK4543","IE0009356076.USD","BK4573","GFS","LU0979878070.USD","LU1951200564.SGD","BK4503","LU1303367103.USD","LU1803068979.SGD","IE00BMPRXN33.USD","LU0719512351.SGD","LU0889565833.HKD","BK4141","LU1989764664.SGD","LU2098885051.SGD","LU0109392836.USD","IE0004445239.USD","LU0198837287.USD","LU0823421416.USD","BK4554","LU0823421333.USD","LU0642271901.SGD","BK4585","LU0823434583.USD","LU1242518931.SGD","LU1880398554.USD","IE00BMPRXR70.SGD","LU1852331112.SGD","LU0056508442.USD","LU0390134368.USD","API","BK4139","LU0082616367.USD","BK4532"],"gpt_icon":1},{"id":"2522235948","title":"Is Kodiak Sciences Inc. (KOD) The Hot Biotech Stock Under $5?","url":"https://stock-news.laohu8.com/highlight/detail?id=2522235948","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522235948?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 03:58","pubTimestamp":1743019139,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Kodiak Sciences Inc.  stands against other hot biotech stocks under $5.A major factor in this upturn is the expected change in the Federal Reserve’s interest rate policies. Biotech needs lots of capital for expensive R&D and clinical tests, making it sensitive to shifting rate trends.Genetic Engineering and Biotechnology Newsnoted that lower rates increase capital availability, helping biotech companies extend operations, attract venture funds, and speed up drug development. Analysts think a rate cut could free up billions in sidelined investment money for struggling new biotech companies seeking stable funding.To identify the 10 Hot Biotech Stocks Under $5, we screened for companies in the biotechnology sector trading below $5 per share while meeting key financial and growth criteria. We focused on stocks with a strong market capitalization, ensuring they had a solid f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kodiak-sciences-inc-kod-hot-195859694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVIW.SI","BK4505","LU1852331112.SGD","NQmain","BK4585","LU1951198990.SGD","LU1242518857.USD","LU0390134368.USD","USAW.SI","IE0009356076.USD","LU1242518931.SGD","LU1923623000.USD","LU0109392836.USD","LU0889565833.HKD","LU0823421333.USD","LU1064131342.USD","BK4512","IE00B5949003.HKD","BK4532","LU1951200564.SGD","LU0979878070.USD","BK4139","QID","BK4566","QLD","LU0056508442.USD","PSQ","BK4573","BK4605","BK4588","BK4554","KOD","BK4534","LU0823421416.USD","TSYW.SI","TQQQ","IE00BMPRXR70.SGD","LU0823434740.USD","MNQmain","LU0081259029.USD","LU2264538146.SGD","LU0823434583.USD","BK4529","BK4575","LU0127658192.USD","SQQQ",".IXIC","USJW.SI"],"gpt_icon":1},{"id":"2521235657","title":"Kodiak Sciences Inc  expected to post a loss of 88 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2521235657","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521235657?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 20:37","pubTimestamp":1742819826,"startTime":"0","endTime":"0","summary":"Kodiak Sciences Inc  expected to post a loss of88cents a share - Earnings Preview Kodiak Sciences Inc KOD.OQ KOD.O is expected to show no change in quarterly revenue when it reports  results on March ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nL5N3Q70Y5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOD"],"gpt_icon":0},{"id":"2521714099","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2521714099","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521714099?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 18:00","pubTimestamp":1742810400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Comp de San Bas                                  4Q       .36       AMC. ·Oklo Inc. Class A                               4Q      (.07)      AMC. ·Core & Main Inc.                                 4Q       .36       BMO. ·McCormick & Co                                 1Q       .64   6:30 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANTX","EDAP","WOOF","XFOR","SLRN","GRDN","CRMD","MDAI","ALUR","SCS","PAYS","SURG","CALC","TEN","KBH","MKC","RVPH","THRD","SKYX","ACRV","CHWY","AFMD","OBIO","UNCY","KOD","ABL","BCAB","RLMD","WGO","CLSD","CTAS","IVA","CNXC","GOVX","LPTX","MREO","NUTX","DLTR","FBIO","IKT","PDSB","BEEM","PAYX","ZURA","IOBT","CDLR","SDST","WBA","DERM","MLKN"],"gpt_icon":0},{"id":"2518072238","title":"KOD Completes Enrollment in Phase III Study for Eye Disease Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2518072238","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518072238?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 22:39","pubTimestamp":1741703940,"startTime":"0","endTime":"0","summary":"Kodiak SciencesKOD announced that it has completed enrollment in a late-stage study of tarcocimab tedromer in patients with diabetic retinopathy . Per KOD, more than 250 patients have been enrolled in the phase III GLOW2 study, surpassing the initial enrollment target. With a 48-week treatment duration, all patients are expected to complete their primary endpoint visits by the end of January 2026. The top-line clinical data is anticipated to be announced in the first quarter of 2026.In late 2023, Kodiak rebooted the development program of tarcocimab following positive phase III results from the GLOW1 study, which evaluated the treatment in patients with moderately severe to severe non-proliferative diabetic retinopathy. Leveraging the GLOW1 study's success, Kodiak initiated the GLOW2 study to further investigate tarcocimab for DR and began dosing patients in May 2024. Enrolled DR patients will receive tarcocimab on extended dosing intervals, including six-month dosing for all patients.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kod-completes-enrollment-phase-iii-143900570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1880398554.USD","BMRN","BK4612","BK4614","LU2250418816.HKD","IE0009356076.USD","BK4578","IE00B3T34201.USD","LU0127658192.USD","LU2360106780.USD","BK4554","LU1951200564.SGD","KOD","IE00BSNM7G36.USD","LU1803068979.SGD","LU0320765992.SGD","LU0823434583.USD","BK4585","III","LU1988902786.USD","LU2468319806.SGD","LU1316542783.SGD","LU1066051498.USD","BK4550","BK4573","BK4141","LU0109394709.USD","LU0082616367.USD","LU2054465674.USD","BK4583","LU1839511570.USD","LU2098885051.SGD","CORT","IE00B19Z3581.USD","LU0390134368.USD","LU0056508442.USD","BK4575","LU0889565833.HKD","IE00B19Z3B42.SGD","LU2089984988.USD","LU2458330243.SGD","LU1951198990.SGD","LU0642271901.SGD","LU1559883803.SGD","GILD","LU1923623000.USD","LU2458330169.SGD","LU0889565916.HKD","LU0719512351.SGD"],"gpt_icon":1},{"id":"2518785975","title":"Kodiak Sciences completes enrollment in GLOW2 Phase 3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2518785975","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518785975?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 04:46","pubTimestamp":1741639568,"startTime":"0","endTime":"0","summary":"Kodiak Sciences (KOD) announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with diabet...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kodiak-sciences-completes-enrollment-in-glow2-phase-3-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kodiak-sciences-completes-enrollment-in-glow2-phase-3-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","KOD","BK4139"],"gpt_icon":0},{"id":"2518578368","title":"Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients With Diabetic Retinopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2518578368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518578368?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 04:39","pubTimestamp":1741639166,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nTUA17X3YJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KOD","BK4505"],"gpt_icon":0},{"id":"2518786946","title":"Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2518786946","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518786946?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 04:38","pubTimestamp":1741639080,"startTime":"0","endTime":"0","summary":"Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026.GLOW2 study design mirrors GLOW1 study, which met primary endpoint and all key secondary endpoints with high statistical significance. PALO ALTO, Calif., March 10, 2025 /PRNewswire/ -- Kodiak Sciences Inc. , today announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with diabetic retinopathy .The Phase 3 GLOW2 study is a prospective, randomized, double-masked, multi-center pivotal superiority study designed to evaluate the efficacy and safety of tarcocimab tedromer in treatment-nave patients with diabetic retinopathy . Patients are randomized 1:1 and receive either sham injections or tarcocimab via intravitreal injection at baseline, Week 4, Week 8, Week 20 and Week 44. The primary endpoint is the proportion","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/kodiak-sciences-completes-enrollment-second-203800919.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kodiak-sciences-completes-enrollment-second-203800919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4505","LU1852331112.SGD","BK4585","LU2054465674.USD","IE0004445239.USD","LU1951198990.SGD","LU0198837287.USD","LU1242518857.USD","LU0390134368.USD","IE0009356076.USD","LU1242518931.SGD","LU1923623000.USD","LU0109392836.USD","LU0889565833.HKD","LU0823421333.USD","LU1064131342.USD","BK4512","BK4141","IE00B5949003.HKD","LU0719512351.SGD","BK4543","LU1989764664.SGD","BK4532","GFS","LU1951200564.SGD","LU0979878070.USD","LU1316542783.SGD","LU1988902786.USD","LU1803068979.SGD","BK4139","LU2250418816.HKD","LU0642271901.SGD","BK4566","LU0056508442.USD","BK4605","BK4588","KOD","LU0823421416.USD","IE00BMPRXR70.SGD","LU1880398471.USD","LU2264538146.SGD","BK4614","LU0823434583.USD","LU2360106780.USD","BK4529","BK4575","BK4612","LU0082616367.USD","LU2458330169.SGD"],"gpt_icon":1},{"id":"2517393833","title":"Kodiak Sciences granted orphan designation for tabirafusp alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=2517393833","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517393833?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 07:11","pubTimestamp":1741129867,"startTime":"0","endTime":"0","summary":"Kodiak Sciences (KOD)’ tabirafusp alfa was granted FDA orphan designation as a treatment of uveitic macular edema, according to a post to the agenc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kodiak-sciences-granted-orphan-designation-for-tabirafusp-alfa?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kodiak-sciences-granted-orphan-designation-for-tabirafusp-alfa?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4505","KOD"],"gpt_icon":0},{"id":"2514018713","title":"We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2514018713","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514018713?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 22:29","pubTimestamp":1740493742,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.So should Kodiak Sciences  shareholders be worried about its cash burn?For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.When Might Kodiak Sciences Run Out Of Money?How Is Kodiak Sciences' Cash Burn Changing Over Time?Kodiak Sciences has a market capitalisation of US$234m and burnt through US$147m last year, which is 63% of the company's market value. Given how large that cash bu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/were-keeping-eye-kodiak-sciences-142902723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NQmain","BK4585","PSQ","NVIW.SI","IE00B64PRP62.GBP","BK4588","QLD","BK4112","TSYW.SI","BK4505","BK4139","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BKPKM429.USD",".IXIC","USAW.SI","LU2210150020.SGD","IE00BGHQF748.EUR","LU2095319765.USD","MNQmain","TQQQ","NDAQ","KOD","QID","SQQQ","USJW.SI"],"gpt_icon":1},{"id":"2510434904","title":"Canaccord Genuity Sticks to Their Buy Rating for Kodal Minerals (KOD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2510434904","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510434904?lang=en_us&edition=full_marsco","pubTime":"2025-02-12 15:45","pubTimestamp":1739346332,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Alexander Bedwany from Canaccord Genuity reiterated a Buy rating on Kodal Minerals (KOD – Research Report), with a ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-their-buy-rating-for-kodal-minerals-kod?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-their-buy-rating-for-kodal-minerals-kod?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MTX","KOD"],"gpt_icon":0},{"id":"2508553884","title":"Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2508553884","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508553884?lang=en_us&edition=full_marsco","pubTime":"2025-02-04 20:30","pubTimestamp":1738672200,"startTime":"0","endTime":"0","summary":"PALO ALTO, Calif., Feb. 4, 2025 /PRNewswire/ --Kodiak Sciences Inc. , a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that senior management will present the Company's pipeline program exploring the treatment of glaucoma at the Glaucoma 360 New Horizons Forum 2025 on Friday, February 7, 2025, in San Francisco, CA.Glaucoma is the leading cause of irreversible blindness, affecting approximately 76 million people worldwide. This optic neuropathy progressively damages the optic nerve, leading to partial or total vision loss. Emerging research identifies neuroinflammation as a key driver of optic neuropathy in glaucoma, but the primary focus of glaucoma therapy today is decreasing the elevated intraocular pressure, the only modifiable risk factor of the disease.Kodiak Sciences is a biopharmaceutical company committed to researching, developing, and commercializing ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/kodiak-sciences-present-glaucoma-360-123000753.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kodiak-sciences-present-glaucoma-360-123000753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","FET","BK4179","BK4505","KOD"],"gpt_icon":0},{"id":"2503055417","title":"Here’s Why Kodiak Sciences Inc. (KOD) Is Skyrocketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2503055417","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503055417?lang=en_us&edition=full_marsco","pubTime":"2025-01-14 05:26","pubTimestamp":1736803569,"startTime":"0","endTime":"0","summary":"One of the strongest stock market anomalies is the momentum effect, which is the tendency of recent past winners to outperform the recent past losers. That’s why we decided to take a look at some of the recent past winners in this article. These 24 companies, predominantly involved in the quantum computing, biotechnology, and technology sectors, have performed significantly well in the final quarter of 2024, registering spectacular returns over the 3 months.That said, let’s take a look at the top 24 stocks that have skyrocketed and pose a solid growth opportunity in the coming year. We will also explore how well the stocks have performed throughout the year and what they have in store for 2025.To come up with 24 names, we considered only the stocks that have at least $2 billion in market capitalization and have registered commendable returns in the fourth quarter of 2024.A close up of a scientist in a labcoat admiring the progress of a biotech experiment.Disclosure: None. This article ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-kodiak-sciences-inc-kod-212609196.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","KOD","BK4505"],"gpt_icon":0},{"id":"2501025191","title":"KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2501025191","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501025191?lang=en_us&edition=full_marsco","pubTime":"2025-01-06 21:59","pubTimestamp":1736171940,"startTime":"0","endTime":"0","summary":"Shares of Kodiak Sciences KOD have skyrocketed 270.7% in the past six months fueled by updates from the developmental program of its lead investigational candidate, tarcocimab. It is a novel anti-VEGF antibody biopolymer conjugate, which is being evaluated for treating retinal vascular diseases.In late 2023, Kodiak rebooted the development program of tarcocimab following positive phase III results from the GLOW1 study, which evaluated the treatment in patients with moderately severe to severe non-proliferative diabetic retinopathy. Leveraging the GLOW1 study's success, Kodiak initiated the GLOW2 study in late 2023 to further investigate tarcocimab for diabetic retinopathy  and began dosing patients in May 2024, with enrollment expected to be completed soon. The success of the GLOW2 study is expected to serve as the basis for a single biologics license application submission for tarcocimab, seeking its approval for DR.The revival of tarcocimab in Kodiak's pipeline, after a major setback","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kod-stock-rallies-271-6-135900100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","BK4505","KOD","BK4139","CSTL","CTMX","VNDA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kodiak.com","stockEarnings":[{"period":"1week","weight":-0.1128},{"period":"1month","weight":-0.2971},{"period":"3month","weight":-0.7084},{"period":"6month","weight":0.094},{"period":"1year","weight":-0.4468},{"period":"ytd","weight":-0.7075}],"compareEarnings":[{"period":"1week","weight":-0.0148},{"period":"1month","weight":-0.0654},{"period":"3month","weight":-0.0661},{"period":"6month","weight":-0.0277},{"period":"1year","weight":0.0623},{"period":"ytd","weight":-0.0519}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.06094},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.132442},{"month":3,"riseRate":0,"avgChangeRate":-0.144565},{"month":4,"riseRate":0.5,"avgChangeRate":-0.092981},{"month":5,"riseRate":0.666667,"avgChangeRate":0.125856},{"month":6,"riseRate":0.666667,"avgChangeRate":0.015307},{"month":7,"riseRate":0.5,"avgChangeRate":-0.036052},{"month":8,"riseRate":0.5,"avgChangeRate":-0.040602},{"month":9,"riseRate":0.666667,"avgChangeRate":0.013919},{"month":10,"riseRate":0.666667,"avgChangeRate":0.230496},{"month":11,"riseRate":0.714286,"avgChangeRate":0.300587},{"month":12,"riseRate":0.571429,"avgChangeRate":0.273501}],"exchange":"NASDAQ","name":"Kodiak Sciences Inc.","nameEN":"Kodiak Sciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kodiak Sciences Inc.(KOD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kodiak Sciences Inc.(KOD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kodiak Sciences Inc.,KOD,Kodiak Sciences Inc.股票,Kodiak Sciences Inc.股票老虎,Kodiak Sciences Inc.股票老虎国际,Kodiak Sciences Inc.行情,Kodiak Sciences Inc.股票行情,Kodiak Sciences Inc.股价,Kodiak Sciences Inc.股市,Kodiak Sciences Inc.股票价格,Kodiak Sciences Inc.股票交易,Kodiak Sciences Inc.股票购买,Kodiak Sciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kodiak Sciences Inc.(KOD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kodiak Sciences Inc.(KOD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction